PMID- 31350276
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20200706
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 106
IP  - 3
DP  - 2020 Feb
TI  - Mid-regional proatrial natriuretic peptide for predicting prognosis in 
      hypertrophic cardiomyopathy.
PG  - 196-202
LID - 10.1136/heartjnl-2019-314826 [doi]
AB  - OBJECTIVES: N-terminal probrain natriuretic peptide (NT-proBNP) predicts 
      mortality and the development of heart failure in hypertrophic cardiomyopathy 
      (HCM). Mid-regional proatrial natriuretic peptide (MR-proANP) is a stable 
      by-product of production of atrial natriuretic peptide. We sought to compare the 
      prognostic value of MR-proANP and NT-proBNP in HCM. METHODS: We prospectively 
      enrolled a cohort of patients with HCM from different European centres and 
      followed them. All patients had clinical, ECG and echocardiographic evaluation 
      and measurement of MR-proANP and NT-proBNP at inclusion. RESULTS: Of 357 patients 
      enrolled, the median age was 52 (IQR: 36-65) years. MR-proANP and NT-proBNP were 
      both independently associated with age, weight, New York Heart Association (NYHA) 
      class, left ventricular ejection fraction (LVEF), wall thickness and left atrial 
      dimension. During a median follow-up of 23 months, 32 patients had a primary end 
      point defined as death (n=6), heart transplantation (n=8), left ventricular 
      assist device implantation (n=1) or heart failure hospitalisation (n=17). Both 
      NT-proBNP and MR-proANP (p<10(-4)) were strongly associated with the primary 
      endpoint, and the areas under the receiver operating characteristic (ROC) curves 
      for both peptides were not significantly different. However, in a multiple 
      stepwise regression analysis, the best model for predicting outcome was NYHA 1-2 
      vs 3-4 (HR=0.35, 95% CI 0.16 to 0.77, p<0.01), LVEF (HR=0.96, 95% CI 0.94 to 
      0.98, p=0.0005) and MR-proANP (HR=3.77, 95% CI 2.01 to 7.08, p<0.0001). 
      CONCLUSIONS: MR-proANP emerges as a valuable biomarker for the prediction of 
      death and heart failure related events in patients with HCM.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Begue, Celine
AU  - Begue C
AD  - Departement de Cardiologie, Hopital Pitie-Salpetriere, APHP, Paris, France.
FAU - Morner, Stellan
AU  - Morner S
AD  - Heart Centre and Department of Public Health and Clinical Medicine, Umea 
      University, Umea, Sweden.
FAU - Brito, Dulce
AU  - Brito D
AD  - Hospital de Santa Maria, Lisbon School of Medicine, Lisbon, Portugal.
FAU - Hengstenberg, Christian
AU  - Hengstenberg C
AD  - Cardiology, Medical University of Vienna, Vienna, Austria.
FAU - Cleland, John G F
AU  - Cleland JGF
AD  - Robertson Institute of Biostatistics and Clinical Trials Unit, University of 
      Glasgow, UK.
AD  - Royal Brompton and Harefield Hospitals, Imperial College, London, UK.
FAU - Arbustini, Eloisa
AU  - Arbustini E
AD  - Centre for Inherited Cardiovascular Diseases, IRCCS Foundation, University 
      Hospital Policlinico San Matteo, Pavia, Italy.
FAU - Galve, Enrique
AU  - Galve E
AD  - Cardiovascular Department, Hospital Universitario Valle Hebron, Barcelona, Spain.
FAU - Wichter, Thomas
AU  - Wichter T
AD  - Niels-Stensen-Kliniken, Marienhospital, Heart Center Osnabruck-Bad Rothenfelde, 
      Osnabruck, Germany.
FAU - Richter, Anette
AU  - Richter A
AD  - Klinik fur Innere Medizin Kardiologie, Universitatskilinikum Giessen and Marburg, 
      Marburg, Germany.
FAU - Golmard, Jean-Louis
AU  - Golmard JL
AD  - Department of Biostatistics and Medical Information, Sorbonne University, AP-HP, 
      Hopital Pitie-Salpetriere, Paris, France.
FAU - Bernard, Maguy
AU  - Bernard M
AD  - Biochemistry, Hopital Pitie-Salpetriere, AP/HP, Paris, France.
FAU - Dubourg, Olivier
AU  - Dubourg O
AD  - Cardiology, Ambroise Pare Hospital, Versailles-Saint Quentin University, 
      Boulogne, France.
FAU - Komajda, Michel
AU  - Komajda M
AD  - Cardiology, Hopital Saint Joseph, Paris, France.
FAU - Charron, Philippe
AU  - Charron P
AD  - Cardiology and Genetics, Pitie-Salpetriere Hospital, IHU-ICAN, UMR-S 1166, AP-HP, 
      Sorbonne Universite, Paris, France.
FAU - Isnard, Richard
AU  - Isnard R
AUID- ORCID: 0000-0002-3439-8104
AD  - Departement de Cardiologie, Sorbonne Universite, AP-HP, Hopital 
      Pitie-Salpetriere, Institute of Cardiometabolism and Nutrition (ICAN), ACTION 
      Study Group, INSERM UMRS 1166, Paris 75013, France.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20190726
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (midregional pro-atrial natriuretic peptide, human)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atrial Natriuretic Factor/*blood
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Hypertrophic/blood/*diagnosis/mortality/therapy
MH  - Cause of Death
MH  - Disease Progression
MH  - Europe
MH  - Female
MH  - Heart Failure/blood/*diagnosis/mortality/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Time Factors
OTO - NOTNLM
OT  - MR-proANP
OT  - NT-proBNP
OT  - hypertrophic cardiomyopathy
OT  - natriuretic peptide
COIS- Competing interests: RI has received research grant and honoraria for speaking, 
      committees and advisory boards from Novartis, Servier, Bayer, Pfizer, Amgen. JGFC 
      has received research grant and honoraria for speaking, committees and advisory 
      boards from Amgen, AstraZeneca, BMS, GSK, J&J, Medtronic, Myokardia, Novartis, 
      Novartis, Philips, Pharmacosmos, PharmaNord, Sanofi, Servier, Stealth 
      Biopharmaceuticals, Torrent Pharmaceuticals and Vifor. CH has received proctor 
      fees, speaker honoraria and fees for advisory board from Edwards Lifesciences, 
      Boston Scientific, AstraZeneca, Bayer, Biotronic, Boehringer Ingelheim, Novartis, 
      Pfizer, BMS, Daiichi-Sankyo and Bayer. MK has received honoraria, consultancy 
      fees or speaker bureau fees from Novartis, Servier, MSD, BMS, Amgen, Sanofi, Novo 
      Nordisk.
EDAT- 2019/07/28 06:00
MHDA- 2020/07/07 06:00
CRDT- 2019/07/28 06:00
PHST- 2019/02/21 00:00 [received]
PHST- 2019/06/24 00:00 [revised]
PHST- 2019/07/01 00:00 [accepted]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2019/07/28 06:00 [entrez]
AID - heartjnl-2019-314826 [pii]
AID - 10.1136/heartjnl-2019-314826 [doi]
PST - ppublish
SO  - Heart. 2020 Feb;106(3):196-202. doi: 10.1136/heartjnl-2019-314826. Epub 2019 Jul 
      26.